Budapest pharmaceutical company Gedeon Richter Plc Monday disclosed the availability of its EC ( European Commission) approved biosimilar teriparatide Terrosa across Europe for the treatment of osteoporosis.
The EC approval of the company's Terrosa applies to all 28 European Union (EU) member states and European Economic Area (EEA) member states.
Terrosa, Eli Lilly's Forsteo, is used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
In addition, the biosimilar teriparatide has been developed by Richter-Helm BioTec GmbH & Co KG and launched under the label Terrosa by Richter via its affiliates in Europe immediately following the patent expiry of the reference product in August 2019.
According to the company, teriparatide is biosimilar to the biologically active fragment of the human parathyroid hormone, and replaces the natural hormone and stimulates bone formation. Teriparatide is used for the treatment of osteoporosis as it reduces the risk of bone fracture in various patient groups. Osteoporosis can occur in both men and women as a side effect of glucocorticoid treatment.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT